Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2014 | 06-2014 | 03-2014 | 12-2013 | 09-2013 | |
| Sales | 10,972 | 7,295 | 8,275 | 10,847 | 8,991 |
| Gross Profit | 10,972 | 7,295 | 8,275 | 10,847 | 8,991 |
| Operating Expenses | 56,171 | 52,300 | 277,339 | 40,439 | 41,225 |
| Operating Income | -45,199 | -45,005 | -269,064 | -29,592 | -32,234 |
| Other Income | 1,277 | 616 | 251 | 256 | 278 |
| Pre-tax Income | -43,922 | -44,389 | -268,813 | -29,336 | -31,956 |
| Income Tax | 67 | -315 | -17,870 | 3,021 | -2,270 |
| Net Income Continuous | -43,989 | -44,074 | -250,943 | -32,357 | -29,686 |
| Net Income | $-43,989 | $-44,074 | $-250,943 | $-32,357 | $-29,686 |
| EPS Basic Total Ops | -0.58 | -0.58 | -3.70 | -0.53 | -0.48 |
| EPS Basic Continuous Ops | -0.58 | -0.58 | -3.70 | -0.53 | -0.48 |
| EPS Diluted Total Ops | -0.58 | -0.58 | -3.70 | -0.53 | -0.48 |
| EPS Diluted Continuous Ops | -0.58 | -0.58 | -3.70 | -0.53 | -0.48 |
| EBITDA(a) | $-42,082 | $-42,137 | $-266,464 | $-26,965 | $-29,470 |